Continue Reading
Full article on Unknown
HSBC Cuts Zoetis Inc. (ZTS)’s Price Target To $140 From $180, Keeps Buy Rating
Market Intelligence Analysis
AI-Powered
Why This Matters
HSBC lowered the price target for Zoetis Inc. (ZTS) to $140 from $180, while maintaining a Buy rating, indicating a decrease in expected stock value but still a positive outlook.
Market Impact
Market impact analysis based on bearish sentiment with 71% confidence.
Sentiment
Bearish
AI Confidence
71%
Article Context
Note: This is a brief excerpt for context. Click below to read the full article on the original source.
Zoetis Inc. (NYSE:ZTS) is among the 11 Most Oversold S&P 500 Stocks Heading into 2026. On December 10, HSBC slashed its price target on the stock to $140 from $180, as part of the firm’s broader overview of pharmaceutical stocks for 2026. However, the investment bank maintained its earlier Buy rating for the shares. It […]
Original article published by
Unknown
on December 13, 2025.
Analysis and insights provided by AnalystMarkets AI.
Analysis and insights provided by AnalystMarkets AI.